References
- Bianchi M, Roghmann F, Becker A, Sukumar S, Briganti A, Menon M, et al. Age-stratified distribution of metastatic sites in bladder cancer: A population-based analysis. Can Urol Assoc J 2014; 8: E148-58. 10.5489/cuaj.787
- Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011; 79: 965-76. 10.1016/j.ijrobp.2010.11.026
- Taneichi H, Kaneda K, Takeda N, Abumi K, Satoh S. Risk factors and probability of vertebral body collapse in metastases of the thoracic and lumbar spine. Spine (Phila Pa 1976) 1997; 22: 239-45.
- Foerster R, Habermehl D, Bruckner T, Bostel T, Schlampp I, Welzel T, et al. Spinal bone metastases in gynecologic malignancies: a retrospective analysis of stability, prognostic factors and survival. Radiat Oncol 2014; 9: 194. 10.1186/1748-717X-9-194
- Rief H, Bischof M, Bruckner T, Welzel T, Askoxylakis V, Rieken S, et al. The stability of osseous metastases of the spine in lung cancer - a retrospective analysis of 338 cases. Radiat Oncol 2013; 8: 200. 10.1186/1748-717X-8-200
- Schlampp I, Rieken S, Habermehl D, Bruckner T, Förster R, Debus J, et al. Stability of spinal bone metastases in breast cancer after radiotherapy: a retrospective analysis of 157 cases. Strahlenther Onkol 2014; 190: 792-7. 10.1007/s00066-014-0651-z
- Foerster R, Eisele C, Bruckner T, Bostel T, Schlampp I, Wolf R, et al. Bone density as a marker for local response to radiotherapy of spinal bone metastases in women with breast cancer: a retrospective analysis. Radiat Oncol 2015; 10: 62. 10.1186/s13014-015-0368-x
- Rief H, Petersen LC, Omlor G, Akbar M, Bruckner T, Rieken S, et al. The effect of resistance training during radiotherapy on spinal bone metastases in cancer patients - a randomized trial. Radiother Oncol 2014; 112: 133-9. 0.1016/j.radonc.2014.06.008
- Bostel T, Förster R, Schlampp I, Wolf R, Serras AF, Mayer A, et al. Stability, prognostic factors and survival of spinal bone metastases in malignant melanoma patients after palliative radiotherapy. Tumori 2016; 102: 156-61. 10.5301/tj.5000382
- Schlampp I, Lang H, Förster R, Wolf R, Bostel T, Bruckner T, et al. Stability of spinal bone metastases and survival analysis in renal cancer after radiotherapy. Tumori 2015; 101: 614-20. 10.5301/tj.5000370
- Abe T, Shinohara N, Harabayashi T, Sazawa A, Maruyama S, Suzuki S, et al. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. Eur Urol 2007; 52: 1106-13. 10.1016/j.eururo.2007.02.052
- Bellmunt J, Albanell J, Paz-Ares L, Climent MA, Gonzalez-Larriba JL, Carles J, et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 2002; 95: 751-7. 10.1002/cncr.10762
- Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997; 15: 2564-9. 10.1200/jco.1997.15.7.2564
- Habermehl D, Haase K, Rieken S, Debus J, Combs SE. Defining the role of palliative radiotherapy in bone metastasis from primary liver cancer: an analysis of survival and treatment efficacy. Tumori 2011; 97: 609-13. 10.1700/989.10720
- Rief H, Heinhold M, Bruckner T, Schlampp I, Forster R, Welzel T, et al. Quality of life, fatigue and local response of patients with unstable spinal bone metastases under radiation therapy--a prospective trial. Radiat Oncol 2014; 9: 133. 10.1186/1748-717X-9-133
- Chow R, Hoskin P, Chan S, Mesci A, Hollenberg D, Lam H, et al. Efficacy of multiple fraction conventional radiation therapy for painful uncomplicated bone metastases: A systematic review. Radiother Oncol 2017; 122: 323-31. 10.1016/j.radonc.2016.12.031
- Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 2010; 15: 382-9. 10.1007/s10147-010-0074-5